Impediments to successful immunotherapy

Pharmacology and Therapeutics

Volumn 81, Issue 2, 1999, Pages 111-119

  Hersey, P ^a  

^a Oncology and Immunology Unit   (Australia)

Author keywords

Anergy; Antigen loss; Resistance to apoptosis; Suppressive factors; T cell migration; Therapeutic strategies

Indexed keywords

CANCER ANTIBODY; FAS LIGAND; HLA ANTIGEN; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR;

APOPTOSIS; CELLULAR IMMUNITY; CLONAL ANERGY; IMMUNE RESPONSE; IMMUNOTHERAPY; LYMPHOCYTE; PRIORITY JOURNAL; REVIEW; TUMOR CELL; TUMOR GROWTH; TUMOR IMMUNITY;

ANTIGENS, NEOPLASM; APOPTOSIS; CELL MOVEMENT; IMMUNOSUPPRESSION; IMMUNOTHERAPY; NEOPLASMS; T-LYMPHOCYTES;

EID: 0033046828     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(98)00038-2     Document Type: Review

References (92)

1. Adema G.J., Hartgers F., Verstraten R., de Vries E., Marland G., Menon S., Foster J., Xu Y., Nooyen P., McClanahan T., Bacon K.B., Figdor C.G. A dendritic-cell-derived C-C chemokine that preferentially attracts naive T cells. Nature. 387:1997;713-715.
2. Ahn M.-C., Siziopikou K.P., Plate J.M.D., Casey L., Silver M., Harris J.E., Braun D.P. Modulation of tumoricidal function in alveolar macrophages from lung cancer patients by interleukin-6. Cancer Immunol. Immunother. 45:1997;37-44.
3. Albright J.F., Oppenheim J.J. Contributions of basic immunology to human health. FASEB J. 5:1991;265-270.
4. Balch C.M., Dougherty P.A., Tilden A.B. Excessive prostaglandin E2 production by suppressor monocytes in head and neck cancer patients. Ann. Surg. 196:1982;645-650.
5. Balch C.M., Dougherty P.A., Cloud G.A., Tilden A.B. Prostaglandin E2-mediated suppression of cellular immunity in colon cancer patients. Surgery. 95:1984;71-77.
6. Bhardwaj R.S., Schwarz E., Becher E., Mahnke K., Aragane Y., Schwarz T., Luger T.A. Pro-opiomelanocortin-derived peptides induce IL-10 production in human monocytes. J. Immunol. 156:1996;2517-2521.
7. Bodmer S., Strommer K., Frei K., Siepl C., De Tribolet N., Heid I., Fontana A. Immunosuppression and transforming growth factor-β in glioblastoma. J. Immunol. 143:1989;3222-3229.
8. Boyano M.D., Garcia-Vazquez M.D., Gardeazabal J., Garcia de Galdeano A., Smith-Zubiaga I., Canavate M.L., Raton J.A., Bilbao I., Diaz-Perez J.L. Serum-soluble IL-2 receptor and IL-6 levels in patients with melanoma. Oncology. 54:1997;400-406.
9. Brune M., Hellstrand K. Remission maintenance therapy with histamine and interleukin-2 in acute myelogenous leukaemia. Br. J. Haematol. 92:1996;620-626.
10. Chen Q., Daniel V., Maher D.W., Hersey P. Production of IL-10 by melanoma cells. examination of its role in immunosuppression mediated by melanoma Int. J. Cancer. 56:1994;755-760.
11. Cochran A.J., Wen D.R., Farzad Z., Stene M.A., McBride W., Lana A.M., Hoon D.S., Morton D.L. Immunosuppression by melanoma cells as a factor in the generation of metastatic disease. Anticancer Res. 9:1989;859-864.
12. Cohen E.P., Kim T.S. Neoplastic cells that express low levels of MHC class I determinants escape host immunity. Semin. Cancer Biol. 5:1994;419-428.
13. D'Andrea A., Aste-Amezaga M., Valiante N.M., Ma X., Kubin M., Trinchieri G. Interleukin-10 inhibits human lymphocyte IFN-γ production by suppressing natural killer cell stimulatory factor/interleukin12 synthesis in accessory cells. J. Exp. Med. 178:1993;1041-1048.
14. de Waal Malefyt R., Haanen J., Spits H., Roncarolo M.-G., te Velde A., Figdor C., Johnson K., Kastelein R., Yssel H., de Vries J.E. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J. Exp. Med. 174:1991;915-924.
15. Ding L., Linsley P.S., Huang L.-Y., Germain R.N., Shevach E.M. IL-10 inhibits macrophage co-stimulatory activity by selectively inhibiting the up-regulation of B7 expression. J. Immunol. 151:1993;1224-1234.
16. Farram E., Nelson M., Nelson D.S., Moon D.K. Inhibition of cytokine production by a tumour cell product. Immunology. 46:1982;603-612.
17. Farzad Z., Cochran A.J., McBride W.H., Gray J.D., Wong V., Morton D.L. Lymphocyte subset alterations in nodes regional to human melanoma. Cancer Res. 50:1990;3585-3588.
18. Ferrone S., Marincola F.M. Loss of HLA class I antigens by melanoma cells. molecular mechanisms, functional significance and clinical relevance Immunol. Today. 16:1995;487-494.
19. Fiorentino D.F., Bond M.W., Mosmann T.R. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J. Exp. Med. 170:1989;2081-2095.
20. Fitzpatrick D.R., Bielefeldt-Ohmann H., Himbeck R.P., Jarnicki A.G., Marzo A.L., Robinson B.W.S. Transforming growth factor-beta. antisense RNA-mediated inhibition affects anchorage-independent growth, tumorigenicity and tumor-infiltrating T-cells in malignant mesothelioma Growth Factors. 11:1994;29-44.
21. Garrido F., Cabrera T., Lopez-Nevot M.A., Ruiz-Cabello F. HLA class I antigens in human tumors. Adv. Cancer Res. 67:1995;155-195.
22. Garrido F., Ruiz-Cabello F., Cabrera T., Perez-Villar J.J., Lopez-Botet M., Duggen-Keen M., Stern P.L. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol. Today. 18:1997;89-95.
23. Gastl G.A., Abrams J.S., Nanus D.M., Oosterkamp R., Silver J., Liu F., Chen M., Albino A.P., Bander N.H. Interleukin-10 production by human carcinoma cell lines and its relationship to interleukin-6 expression. Int. J. Cancer. 55:1993;96-101.
24. Gimmi C.D., Morrison B.W., Mainprice B.A., Gribben J.G., Boussiotis V.A., Freeman G.J., Park S.Y.L., Watanabe M., Gong J., Hayes D.F., Kufe D.W., Nadler L.M. Breast cancer-associated antigen, DF3/MUC1, induces apoptosis of activated human T cells. Nature Med. 2:1996;1367-1370.
25. Grabbe S., Bhardwaj R.S., Mahnke K., Simon M.M., Schwarz T., Luger T.A. alpha-Melanocyte-stimulating hormone induces hapten-specific tolerance in mice. J. Immunol. 156:1996;473-478.
26. Groux H., Bigler M., deVries J.E., Roncarolo M.-G. Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+ T cells. J. Exp. Med. 184:1996;19-29.
27. Hagenbaugh A., Sharma S., Dubinett S.M., Wei S.H.Y., Aranda R., Cheroutre H., Fowell D.J., Binder S., Tsao B., Locksley R.M., Moore K.W., Kronenberg M. Altered immune responses in interleukin 10 transgenic mice. J. Exp. Med. 185:1997;2101-2110.
28. Hahne M., Rimoldi D., Schroter M., Romero P., Schreier M., French L.E., Schneider P., Bornand T., Fontana A., Lienard D., Cerottini J.-C., Tschopp J. Melanoma cell expression of Fas (Apo-1/CD95) ligand. implications for tumor immune escape Science. 274:1996;1363-1366.
29. Hellstrand K., Naredi P., Lindner P., Lundholm K., Rudenstam C.M., Hermodsson S., Asztely M., Hafstrom L. Histamine in immunotherapy of advanced melanoma. a pilot study Cancer Immunol. Immunother. 39:1994;416-419.
30. Hellstrand K., Hermodsson S., Brune M., Naredi P., Carneskog J., Mellqvist U.H. Histamine in cancer immunotherapy. Scand. J. Clin. Lab. Invest. 57:1997;193-202.
31. Hersey P., Bindon C., Czerniecki M., Spurling A., Wass J., McCarthy W. Inhibition of interleukin 2 production by factors released from tumor cells. J. Immunol. 131:1983;2837-2842.
32. Hersh V.M., Drewinko B. Specific inhibition of lymphocyte blastogenic responses to mitogens by a factor produced by cultured human malignant lymphoma cells. Cancer Res. 34:1974;215-220.
33. Huber D., Philipp J., Fontana A. Protease inhibitors interfere with the transforming growth factor-β-independent pathway of tumor cell-mediated immunosuppression. J. Immunol. 148:1992;277-284.
34. Ikeda H., Lethe B., Lehmann F., van Baren N., Baurain J.F., de Smet C., Chambost H., Vitale M., Moretta A., Boon T., Coulie P.G. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity. 6:1997;199-208.
35. Irmler M., Thome M., Hahne M., Schneider P., Hofmann K., Steiner V., Bodmer J.-L., Schroter M., Burns K., Mattmann C., Rimoldi D., French L.E., Tschopp J. Inhibition of death receptor signals by cellular FLIP. Nature. 388:1997;190-195.
36. Jager E., Ringhoffer M., Karbach J., Arand M., Oesch F., Knuth A. Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses. evidence for immunoselection of antigen-loss variants in vivo Int. J. Cancer. 66:1996;470-476.
37. Jager E., Ringhoffer M., Altmannsberger M., Arand M., Karbach J., Jager D., Oesch F., Knuth A. Immunoselection in vivo. independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma Int. J. Cancer. 71:1997;142-147.
38. Jiang J., Sharma S.D., Nakamura S., Lai J.Y., Fink J.L., Hruby V.J., Hadley M.E. The melanotropic peptide, [Nle4,D-Phe7] alpha-MSH, stimulates human melanoma tyrosinase activity and inhibits cell proliferation. Pigment Cell Res. 8:1995;314-323.
39. Jiang J., Sharma S.D., Fink J.L., Hadley M.E., Hruby V.J. Melanotropic peptide receptors. membrane markers of human melanoma cells Exp. Dermatol. 5:1996;325-333.
40. Kerbel R.S. Expression of multi-cytokine resistance and multi-growth factor independence in advanced stage metastatic cancer. Am. J. Pathol. 141:1992;519-524.
41. Kono K., Salazar-Onfray F., Petersson M., Hansson J., Masucci G., Wasserman K., Nakazawa T., Anderson P., Kiessling R. Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell- and natural killer cell-mediated cytotoxicity. Eur. J. Immunol. 26:1996;1308-1313.
42. Krasagakis K., Garbe C., Schrier P.I., Orfanos C.E. Paracrine and autocrine regulation of human melanocyte and melanoma cell growth by transforming growth factor beta in vitro. Anticancer Res. 14:1994;2565-2571.
43. Lang M.S., Oostendorp R.A.J., Simons P.J., Boersma W., Knegt P., van Ewijk W. New monoclonal antibodies against the putative immunosuppressive site of retroviral p15E. Cancer Res. 54:1994;1831-1836.
44. Lehmann F., Marchand M., Hainaut P., Pouillart P., Sastre X., Ikeda H., Boon T., Coulie P.G. Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection. Eur. J. Immunol. 25:1995;340-347.
45. Linnemeyer P.A., Pollack S.B. Prostaglandin E2-induced changes in the phenotype, morphology, and lytic activity of IL-2-activated natural killer cells. J. Immunol. 150:1993;3747-3754.
46. Lipton J.M., Catania A. Anti-inflammatory actions of the neuroimmunomodulator α-MSH. Immunol. Today. 18:1997;140.
47. Liu P.Y., Johansson O. Immunohistochemical evidence of alpha-, beta- and gamma 3-melanocyte stimulating hormone expression in cutaneous malignant melanoma of nodular type. J. Dermatol. 10:1995;203-212.
48. 3H-thymidine uptake by normal stimulated lymphocytes. Oncology. 34:1977;251-254.
49. Luscher U., Filgueira L., Juretic A., Zuber M., Luscher N.J., Heberer M., Spagnoli G.C. The pattern of cytokine gene expression in freshly excised human metastatic melanoma suggests a state of reversible anergy of tumor-infiltrating lymphocytes. Int. J. Cancer. 57:1994;612-619.
50. Maeda H., Shiraishi A. TGF-beta contributes to the shift toward Th2-type responses through direct and IL-10 mediated pathways in tumor-bearing mice. J. Immunol. 156:1996;73-78.
51. Matsuda M., Salazar F., Petersson M., Masucci G., Hansson J., Pisa P., Zhang Q.J., Masucci M.G., Kiessling R. Interleukin 10 pretreatment protects target cells from tumor- and allo-specific cytotoxic T cells and downregulates HLA class I expression. J. Exp. Med. 180:1994;2371-2376.
52. Matsuda M., Petersson M., Lenkei R., Taupin J.L., Magnusson I., Mellstedt H., Anderson P., Kiessling R. Alterations in the signal-transducing molecules of T cells and NK cells in colorectal tumor-infiltrating, gut mucosal and peripheral lymphocytes. correlation with the stage of the disease Int. J. Cancer. 61:1995;765-772.
53. Miescher S., Whiteside T.L., Moretta L., Von Fliedner V. Clonal and frequency analyses of tumor-infiltrating T lymphocytes from human solid tumors. J. Immunol. 138:1987;4004-4011.
54. Miescher S., Stoeck M., Qiao L., Barras C., Barrelet L., Von Fliedner V. Proliferative and cytolytic potentials of purified human tumor-infiltrating T lymphocytes. Impaired response to mitogen-driven stimulation despite T-cell receptor expression. Int. J. Cancer. 42:1988;659-666.
55. Mizoguchi H., O'Shea J.J., Longo D.L., Loeffler C.M., McVicar D.W., Ochoa A.C. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science. 258:1992;1795-1798.
56. Mohagheghpour N., Parhami B., Dowlatshahi K., Kadjehnouri D., Elder J.H., Chisari F.V. Immunoregulatory properties of human esophageal tumor extract. J. Immunol. 122:1979;1350-1358.
57. Moretti S., Pinzi C., Berti E., Spallanzani A., Chiarugi A., Boddi V., Reali U.M., Giannoti B. In situ expression of transforming growth factor beta is associated with melanoma progression and correlates with Ki67, HLA-DR and beta 3 integrin expression. Melanoma Res. 7:1997;313-321.
58. Nakagomi H., Pisa P., Pisa E.K., Yamamoto Y., Halapi E., Backlin K., Juhlin C., Kiessling R. Lack of interleukin-2 (IL-2) expression and selective expression of IL-10 mRNA in human renal cell carcinoma. Int. J. Cancer. 63:1995;366-371.
59. Nguyen T.D., Smith M.J., Hersey P. Contrasting effects of T cell growth factors on T cell responses to melanoma in vitro. Cancer Immunol. Immunother. 43:1997;345-354.
60. Niehans G.A., Brunner T., Frizelle S.P., Liston J.C., Salerno C.T., Knapp D.J., Green D.R., Kratzke R.A. Human lung carcinomas express Fas ligand. Cancer Res. 57:1997;1007-1012.
61. O'Connell J., O'Sullivan G.C., Collins J.K., Shanahan F. The Fas counterattack. Fas-mediated T cell killing by colon cancer cells expressing Fas ligand J. Exp. Med. 184:1996;1075-1082.
62. Oppenheimer-Marks N., Kavanaugh A.F., Lipsky P.E. Inhibition of the transendothelial migration of human T lymphocytes by prostaglandin E2. J. Immunol. 152:1994;5703-5713.
63. O'Sullivan G.C., Corbett A.R., Shanahan F., Collins J.K. Regional immunosuppression in esophageal squamous cancer. J. Immunol. 157:1996;4717-4720.
64. Piali L., Fichtel A., Terpe H.-J., Imhof B.A., Gisler R.H. Endothelial vascular cell adhesion molecule 1 expression is suppressed by melanoma and carcinoma. J. Exp. Med. 181:1995;811-816.
65. Rabinowich H., Suminami Y., Reichert T.E., Crowley-Nowick P., Bell M., Edwards R., Whiteside T.L. Expression of cytokine genes or proteins and signaling molecules in lymphocytes associated with human ovarian carcinoma. Int. J. Cancer. 68:1996;276-284.
66. Reichert T.E., Rabinowich H., Johnson J.T., Whiteside T.L. Human immune cells in the tumor microenvironment. mechanisms responsible for signaling and functional defects J. Immunother. 21:1998;295-306.
67. 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J. Natl. Cancer Inst. 88:1996;100-108.
68. Rivoltini L., Barracchini K.C., Viggiano V., Kawakami Y., Smith A., Mixon A., Restifo N.P., Topalian S.L., Simonis T.B., Rosenberg S.A., Marincola F.M. Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes. Cancer Res. 55:1995;3149-3157.
69. Rogge L., Barberis-Maino L., Biffi M., Passini N., Presky D.H., Gubler U., Sinigaglia F. Selective expression of an interleukin-12 receptor component by human T helper 1 cells. J. Exp. Med. 185:1997;825-831.
70. Rokhlin O.W., Bishop G.A., Hostager B.S., Waldschmidt T.J., Sidorenko S.P., Pavloff N., Kifer M.C., Umansky S.R., Glover R.A., Cohen M.B. Fas-mediated apoptosis in human prostatic carcinoma cell lines. Cancer Res. 57:1997;1758-1768.
71. Roszman T., Elliott L., Brooks W. Modulation of T-cell function by gliomas. Immunol. Today. 12:1991;370-374.
72. Ruffini P.A., Rivoltini L., Silvani A., Boiardi A., Parmiani G. Factors, including transforming growth factor β, released in the glioblastoma residual cavity, impair activity of adherent lymphokine-activated killer cells. Cancer Immunol. Immunother. 36:1993;409-416.
73. Salvadori S., Zier K. Molecular basis of T cell dysfunction in cancer is influenced by the paracrine secretion of tumor-derived IL-2. J. Immunol. 156:1996;2927-2932.
74. Schauer E., Trautinger F., Koeck A., Schwarz A., Bhardwaj R.S., Simon M.M., Ansel J.C., Schwarz T., Luger T.A. Proopiomelanocortin-derived peptides are synthesized and released by human keratinocytes. J. Clin. Invest. 93:1994;2258-2262.
75. Schmid P., Itin P., Rufli T. In situ analysis of transforming growth factors-beta (TGF-beta 1, TGF-beta 2, TGF-beta 3), and TGF-beta type II receptor expression in malginant melanoma. Carcinogenesis. 16:1995;1499-1503.
76. Seliger B., Maeurer M.J., Ferrone S. TAP off - tumors on. Immunol. Today. 18:1997;292-299.
77. Singh S., Ross S.R., Acena M., Rowley D.A., Schreiber H. Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells. J. Exp. Med. 175:1992;139-146.
78. Snyderman R., Cianciolo G.J. Immunosuppressive activity of the retroviral envelope protein P15E and its possible relationship to neoplasia. Immunol. Today. 5:1984;240-244.
79. Strand S., Hofmann W.J., Hug H., Muller M., Otto G., Strand D., Mariani S.M., Stremmel W., Krammer P.H., Galle P.R. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - a mechanism of immune evasion? Nature Med. 2:1996;1361-1366.
80. Tartour E., Blay J.Y., Dorval T., Escudier B., Mosseri V., Douillard J.Y., Deneux L., Gorin I., Negrier S., Mathiot C., Pouillart P., Fridman W.H. Predictors of clinical response to interleukin-2 based immunotherapy in melanoma patients. a French multi-institutional study J. Clin. Oncol. 14:1996;1697-1703.
81. Thomas W.D., Hersey P. CD4 T cells kill melanoma cells by mechanisms that are independent of Fas (CD95). Int. J. Cancer. 75:1998;384-390. a.
82. Thomas W.D., Hersey P. TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells. J. Immunol. 161:1998;2195-2200. b.
83. Tilg H., Dinarello C.A., Mier J.W. IL-6 and APPs. anti-inflammatory and immunosuppressive mediators Immunol. Today. 18:1997;428-432.
84. Tzai T.S., Shiau A.L., Lin C.S., Wu C.L., Lin J.S.N. Modulation of the immunostimulating effect of autologous tumor vaccine by anti-TGF-beta antibody and interferon-alpha on murine MBT-2 bladder cancer. Anticancer Res. 17:1997;1073-1078.
85. Van Belle P., Rodeck U., Nuamah I., Halpern A.C., Elder D.E. Melanoma-associated expression of transforming growth factor-beta isoforms. Am. J. Pathol. 148:1996;1887-1894.
86. VanHeyningen T.K., Collins H.L., Russell D.G. IL-6 produced by macrophages infected with mycobacterium species suppresses T cell responses. J. Immunol. 158:1997;330-337.
87. Werkmeister J., Zaunders J., McCarthy W., Hersey P. Characterization of an inhibitor of cell division released in tumour cell cultures. Clin. Exp. Immunol. 41:1980;487-496. a.
88. Werkmeister J., Zbroja R., McCarthy W., Hersey P. Detection of an inhibitor of cell division in cultures of tumour cells with immunosuppressive activity in vitro. Clin. Exp. Immunol. 40:1980;168-177. b.
89. Wick M., Dubey P., Koeppen H., Siegel C.T., Fields P.E., Chen L., Bluestone J.A., Schreiber H. Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy. J. Exp. Med. 186:1997;229-238.
90. Wiley S.R., Schooley K., Smolak P.J., Din W.S., Huang C.-P., Nicholl J.K., Sutherland G.R., Smith T.D., Rauch C., Smith C.A., Goodwin R.G. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 3:1995;673-682.
91. Zhang Q.J., Brunner T., Carter L., Dutton R.W., Rogers P., Bradley L., Sato T., Reed J.C., Green D., Swain S.L. Unequal death in T helper cell (Th)1 and Th2 effectors. Th1, but not Th2, effectors undergo rapid Fas/FasL-mediated apoptosis J. Exp. Med. 185:1997;1837-1849.
92. Zier K., Gansbacher B., Salvadori S. Preventing abnormalities in signal transduction of T cells in cancer. the promise of cytokine gene therapy Immunol. Today. 17:1996;39-45.